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Abstract TR-644 is a novel combretastatin A-4 (CA-4)
analogue endowed with potent microtubule depolymerizing
activity superior to that of the lead compound and it also
has high affinity to colchicines binding site of tubulin. We
tested TR-644 anti-angiogenic effects in human umbilical
endothelial cells (HUVEC). It showed no significant effects
on the growth of HUVEC cells at concentrations below
1,000 nM, but at much lower concentrations (10–100 nM)
it induced inhibition of capillary tube formation, inhibition
of endothelial cell migration and affected endothelial cell
morphology as demonstrated by the disruption of the
microtubule network. TR-644 also increased permeability
of HUVEC cells in a time dependent manner. The
molecular mechanism for the anti-vascular activity of TR-
644 was investigated in detail. TR-644 caused G2/M arrest
in endothelial cells and this effect correlated with down-
regulation of the expression of Cdc25C and Cdc2Tyr15.
Moreover TR-644 inhibited VEGF-induced phosphoryla-
tion of VE-cadherin but did not prevent the VEGF-induced
phosphorylation of FAK. In chick chorioallantoic mem-
brane in vivo assay, TR-644 (0.1–1.0 pmol/egg) efficiently
counteracted the strong angiogenic response induced by
FGF. Also CA-4, used as reference compound, caused an
antagonistic effect, but in contrast, it induced per se, a
remarkable angiogenic response probably due to an
inflammatory reaction in the site of treatment. In a mice
allogenic tumor model, immunohistochemical staining of
tumors with anti-CD31 antibody showed that TR-644 sig-
nificantly reduced the number of vessel, after 24 h from the
administration of a single dose (30 mg/Kg).
Keywords Angiogenesis  HUVEC  Vascular disrupting
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Introduction
The microtubule system of eukaryotic cells is a critical
element in a variety of fundamental cellular processes,
such as cell division, formation and maintenance of cell
shape, regulation of motility, cell signalling, secretion and
intracellular transport [1]. Among the various strategies
developed to block mitosis, microtubules represent an
attractive target for numerous small natural and synthetic
molecules that inhibit the formation of the mitotic spindle
[1, 2]. Besides the ability to inhibit tumor cell proliferation,
microtubule-targeting drugs have also been shown to have
activity against the vasculature in tumors [3, 4]. Since the
tumor vasculature differs from that of normal tissues, in
recent years, the abnormal structure and function of tumor
blood vessels have been studied in the attempt to attack and
destroy solid tumors. These vascular abnormalities consist
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of temporary occlusions, a rapidly dividing endothelial
population, blind ends, leaky vessels, and a reduction in
blood vessel coverage by pericytes. In addition, the struc-
ture of the tumor blood vessel wall is also abnormal, which
is evident by uneven vessel diameter and defects in their
endothelial lining, as well as the presence of endothelial
cells undergoing apoptosis. In contrast, normal vasculature
is organized with vessels close enough to each other to
ensure adequate nutrient and oxygen supply to all cells.
Tumor-vascular disrupting agents (VDAs) are a new class
of anti-cancer drugs that show strong promise in treating a
variety of solid tumors [4]. In contrast to antiangiogenic
therapy, which inhibits the outgrowth of new blood vessels,
VDAs treatments selectively attack the existing tumor
vasculature. Several low-molecular-weight VDAs are cur-
rently in clinical trials or undergoing preclinical testing.
One of the most important antimitotic agents and vascular
disrupting agents is combretastatin A-4 (CA-4, Fig. 1).
CA-4, isolated from the bark of the South African tree
Combretum caffrum is one of the well-known natural
molecules that strongly inhibits tubulin polymerization by
binding to the colchicine binding site. CA-4 shows potent
cytotoxicity against a wide variety of human cancer cell
lines, including those displaying multidrug resistant. A
water-soluble disodium phosphate derivative of CA-4
(named CA4-P) has shown promising results in human
cancer clinical trials. The proposed mechanism of CA4-P
for rapid tumor vascular shutdown assumes that the com-
pound induces changes in endothelial-cell shape, plasma
membrane blebbing, and increases the permeability of cell
monolayers. These changes in endothelial cells result in
increases in vascular resistance to blood flow and increases
vascular permeability and in vasoconstriction, subse-
quently leading to vascular shutdown. CA4 has tumor
vascular damaging effects at well-tolerated doses of CA4-P
in animal models [5]. Recently, CA4-P has received orphan
drug designation for the treatment of anaplastic thyroid
cancer, medullary thyroid cancer, and stage IV papillary or
follicular thyroid cancer. Despite its efficacy CA4-P pre-
sents some side-effects in particular tumor pain.
Therefore, many synthetic analogues were synthesized
making structural modification of the CA4 in order to develop
new compounds with more activity and fewer adverse reac-
tions. Previous structure–activity relationship studies dem-
onstrated that both the 30,40,50-trimethoxy substitution pattern
on the A-ring and the cis-olefin configuration at the bridge
were fundamental requirements for optimal activity, while
B-ring structural modifications were tolerated by the target [6].
However, the cis-configuration of CA-4 is prone to isomerize
to the thermodynamically more stable trans-form during
storage and metabolism, resulting in a dramatic decrease in its
activity [7]. Thus, to retain the appropriate geometry of the two
adjacent aryl groups required for a potent bioactivity, chemi-
cally stable cis-restricted derivatives of CA-4 were obtained
by incorporating the olefinic double bond with vicinal diaryl-
substituted five-member aromatic heterocyclic rings, such as
pyrazole [8], imidazole [9], thiazole [10], furazan (1,2,5-
oxadiazole) [11], isoxazole [12], oxazole [8], 1,2,3-thiadiazole
[13], triazole [14] and 1,2,3,4-tetrazole [10]. We recently
synthesized [15] a new series of 2-amino-4-(30,40,50-trime-
thoxyphenyl)-5-aryl thiazoles in which we identified com-
pound TR-644 as the most active compound (Fig. 1). It has
been shown that this compound is endowed with high anti-
proliferative effects with IC50 values in the nanomolar range in
different cancer cell lines. Here we show that this compound is
endowed with pronounced in vitro antivascular effects at sub-
toxic concentrations and appears to disrupt the vasculature
in vivo both in tumor tissue and in the chick chorioallantoic
membrane, without any evident toxic effect.
Materials and methods
Drugs and cell culture
TR-644 was synthesized as previously described [15].
Combretastatin A4 (CA4) and CA4-P were synthesized as
described [16–18]. HUVECs were prepared from human
humbelical cord veins, as previously described [19]. The
adherent cells were maintained in M200 medium additioned
by LSGS (Low Serum Growth Supplement), containing
FBS, Hydrocortisone, hEGF, bFGF, heparin, gentamycin/
amphotericin (Life technologies, Monza, Italy). Once con-
fluent, the cells were detached by trypsin–EDTA solution
and used in experiments from the first to sixth passages.
BL6-B16 murine melanoma cells were maintained in
DMEM supplemented with 10 % fetal calf serum (FCS).
Cytotoxicity and apoptosis assays
Cytotoxicity assay were carried out with trypan blue test as
described previously [20]. Surface exposure of phosphati-
dylserine on apoptotic cells was measured by flow cytometry
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with a Coulter Cytomics FC500 (Beckman Coulter) using
Annexin-V-Fluos kit to cells according to the manufacturer’s
instructions (Annexin-V Fluos, Roche Diagnostic, Monza,
Italy). Simultaneously the cells were stained with PI.
Colony forming assay
HUVECs were plated at 1 9 103 cells/well in six-well
plates to provide an optimal counting density. Cells were
treated with compounds at different concentration. After
24 h, medium was replaced with fresh one and cells were
cultured for 1–2 weeks until well-defined colonies had
formed (replacing culture medium every 2–3 days). Cells
were briefly washed with 0.9 % saline solution and stained
with 0.5 % crystal violet in 20 % methanol. Colonies of
C50 cells were then counted visually.
Motility assay
Motility assay for HUVECs was based on ‘‘scratch’’
wounding of a confluent monolayer [21]. Briefly, HUVECs
(1 9 105) were seeded onto 0.1 % collagen type I (BD
Biosciences, Italy)-coated six well plates in complete
medium until a confluent monolayer was formed. The cells
were scratch wounded using a pipette tip and wells were
washed with PBS to remove the undetached cells. Then,
the cells were treated with the test compounds and at dif-
ferent times from the scratch, the cells were photographed
under a light microscope (109 magnification). At all
indicated time points, the wound width was measured in
four areas and compared with the initial width.
Endothelial cell vessel formation on Matrigel matrix
Matrigel matrix (Basement membrane matrix, BD Biosci-
ences, Italy) was kept at 4 C for 3 h. 230 ll of Matrigel
were added to each well of a 24-well plate. After gelling at
37 C for 30 min, gels were overlaid with 500 ll of
medium containing 6 9 104 HUVEC cells, incubated over
Matrigel for 6 h to allow the capillary tubes to form. Dif-
ferent concentrations of TR-644 were added in the cultures
and incubated for different times and the disappearance of
existing vasculature was monitored and photographed (five
fields for each well: the four quadrants and the center) at a
109 magnification. Phase contrast images were recorded
using a digital camera and save as TIFF files. Image
analysis was carried out using the ImageJ image analysis
software and the following dimensional parameters (per-
cent area covered by HUVECs and total length of HU-
VECs network per field), and topological parameters
(number of meshes and branching points per fields) were
estimated [22]. Values were expressed as percent change
from control cultures grown with complete medium.
Endothelial cell permeability assay
HUVEC cells were seeded at a density of 3 9 105 cells per
well into 24-well cell culture inserts (1.0 lm, Falcon,
Mantova, Italy) and incubated for 24 h to allow a confluent
cell monolayer to form. Drugs at varying concentrations
were added to the cells at the upper chamber and incubated
for different times at 37 C. At the same time, FITC-dex-
tran (Fluorescein Isothiocyanate-dextran 40 kDa, Sigma-
Aldrich, Milano, Italy)—was added to the upper chamber.
The effects of TR-644 and CA4 on HUVEC monolayer
permeability were monitored using a fluorescent plate
reader (Victor3 Perkin Elmer) as measured by increased
fluorescent signal in the lower chamber as a function of
time.
Cell adhesion assay
HUVECs were seeded in six-well plates to provide an
optimal density and treated with compounds at different
concentrations. After 24 h, cells were trypsinized and
plated in quadruplicate on a 96-well plate at 5 9 104 cells
per well. Cells were allowed to attach for 20 min at 37 C,
and then unattached cells were gently removed. Adherent
cells were washed three times with PBS and incubated with
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bro-
mide. MTT test was performed as previously described
[23] to quantify the attached cells.
Immunofluorescence analysis
Cells were fixed in cold 4 % formaldehyde for 15 min,
rinsed and stored prior to analysis. Primary antibody staining
was performed for b-tubulin (mouse, monoclonal 1:1,000,
Sigma-Aldrich, Milano, Italy). After incubation, cells were
washed and incubated with a secondary antibody Alexa
conjugated (1:2,000, Life technologies, Monza, Italy). Cells
were counterstained with DAPI (1:10,000, Sigma-Aldrich,
Milano, Italy). For F-actin visualization the cells were fixed
as above and stained with phalloidin-tetramethylrhodamine
B isothiocyanate conjugate (Sigma-Aldrich, Milano, Italy).
Images were obtained on a video-confocal microscope
(Vico, Ecliple Ti80, Nikon), equipped with a digital camera.
Western blot analysis
HUVECs cells were incubated in the presence of test com-
pounds and, after different times, were collected, centrifuged
and washed two times with ice cold phosphate-buffered
saline (PBS). The pellet was then resuspended in lysis buffer.
After 30 min of incubation in ice, cells were lysed on ice
for 30 min, lysates were centrifuged at 15,0009g at 4 C
for 10 min and the supernatant collected. The protein
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concentration in the supernatant was determined using the
BCA protein assay reagents (Pierce, Milano, Italy). Equal
amounts of protein (10 lg) were resolved using sodium
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE) (7.5–15 % acrylamide gels) and transferred to PVDF
Hybond-p membrane (GE Healthcare, Milano, Italy).
Membranes were blocked with ECL Advance Blocking
Agent (GE Healthcare, Milano, Italy) for 2 h at room tem-
perature. Membranes were then incubated overnight at 4 C
with primary antibodies against, p-cdc2Tyr15, cdc25c (Cell
Signaling, Milano, Italy), cyclin B (BD Biosciences, Italy),
FAKTyr397 (BD Biosciences, Italy) and VE-cadherinTyr658
(Abcam). Membranes were next incubated with peroxidase-
labeled secondary antibodies for 60 min. All membranes
were visualized using ECL Advance (GE Healthcare, Mi-
lano, Italy) and exposed to Hyperfilm MP (GE Healthcare,
Milano, Italy). To ensure equal protein loading, each mem-
brane was stripped and reprobed with anti-b-actin anti-
body(Sigma-Aldrich, Milano, Italy).
CAM assay in fertilized chicken eggs
Alginate pellets containing 0.1–1.0 pmol per pellet of TR-
644 or CA4 were grafted on the chorioallantoic membrane
(CAM) of fertilized chicken eggs at day 11 [24]. After 72 h
new blood vessels converging toward the implant were
counted at 59 magnification under a stereomicroscope.
Tumorigenesis studies
Procedures involving animals and their care conformed
with institutional guidelines that comply with national and
international laws and policies (EEC Council Directive
86/609, OJ L 358, 12 December 1987). Six week old
C57BL/6 mice (Charles River, Calco, Italy) were injected
s.c. into the dorsolateral flank with 105 BL6-B16 murine
melanoma cells in 200 ll—total volume of PBS. When
tumor volume reached 300 mm3 of volume, animals were
treated i.p with 50 ll of CA-4P (30 mg/kg), TR-644
(30 mg/kg) dissolved in DMSO. Twenty-four hours later
tumors where harvested, embedded in OCT-compound
(Bio-Optica) and immediately frozen in liquid nitrogen for
immunohistochemical analysis.
Immunohistochemistry and immunofluorescence
of tumor tissues
Excised tumors were cut with a cryostat in 4–5 lm sec-
tions. Immunohistochemistry was performed by staining
samples with rat anti-mouse CD31 antibody (1:200; BD
Biosciences) and biotinylated goat anti-rat secondary
antibody (1:100; BD Biosciences). The detection of tumor
vasculature was performed using HRP-conjugated
streptavidin (1:500; Jackson ImmunoResearch Laborato-
ries). The microvessel density (MVD) was evaluated by
counting the number of vessels in 5 fields per section, using
a 409 objective. For subsequent experiments, samples
were formalin-fixed and paraffin embedded and then
stained with mouse primary antibody against proliferating
cell nuclear antigen PCNA (1:100; Santa Cruz) and Alexa-
Fluor secondary antibody (1:2,000, Life technologies,
Monza, Italy). Proliferating cells were determined by
counting the number of PCNA-positive cells on DAPI-
positive cells (values expressed as percent of PCNA ?
cells/DAPI ? cells), in 3 fields for each section, with a
409 objective. A staining with hematoxylin and eosin (HE)
was also performed to visualize the histological features of
tumors. All specimens were viewed under a video-confocal
microscope (Vico, Ecliple Ti80, Nikon), equipped with a
digital camera, and images were captured using a 109
objective.
Statistical analyses
Unless indicated differently, the results are presented as
mean ± SEM. The differences between different treat-
ments were analysed, using the two-sided Student’s t test.
P values lower than 0.05 were considered significant.
Results
TR-644 inhibits HUVEC migration and tube formation
To investigate the effects of TR-644 on endothelial cell
migration, we scraped confluent monolayers of HUVEC to
clear space for motile cells to move into. As shown in
Fig. 2 (panels A and B) we observed that TR-644 inhibited
HUVEC migration in a concentration and time-dependent
manner. For comparison, we studied the effects of CA-4 in
the same experimental conditions. CA-4 treatment dis-
played similar effects, with a more pronounced inhibition
of cell migration at the concentration of 5 nM (Fig. 2,
panel C) at which TR-644 is barely effective.
We also tested the effects of TR-644 on tubules for-
mation assay, a well known in vitro angiogenesis test. After
18 h from cells seeding on Matrigel, HUVEC form a rich
meshwork of branching capillary-like tubules with multi-
centric junctions. In the presence of TR-644, at different
concentration and after 3 h of incubation, we observed that
the capillary-like tubes were interrupted (1–10 nM) and at
higher concentration (100 nM) most cells were spherical
either isolated or aggregated in small clumps (Fig. 3, panel
A). These effects started to occur after 1 h of incubation
and further increased after 6 h of incubation (Data not
shown).
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Quantitative image analysis showed that TR-644
(10–100 nM), significantly decreased both dimensional
(percent of area covered by HUVECs, total length per field)
and topological parameters (number of meshes per field,
and number of branching points) of the capillary-like net-
work (Fig. 3, panel B). Similar results were obtained with
CA-4 (Fig. 3, panel B).
Moreover we evaluated the inhibitory effects of TR-
644 on tube formation. In this case, drugs were added
simultaneously at the time of seeding. After 3 h of
incubation we found a strong inhibition of capillary
formation in comparison to untreated cells, in which
we observed the polygonal structures (mesh) already
formed (Fig. 3, panel C). It is interesting to note that in
this case the effect of TR-644 was evident and sig-
nificant also at the lowest concentration used (1 nM)
and was higher than that of CA4 (Fig. 3, panel D),
suggesting that TR-644 strongly intefered with the
ability of HUVEC to form capillary-like structures
in vitro.
TR-644 increases permeability of the vascular
endothelial monolayer
Changes in endothelial cell monolayer permeability also
provide an in vitro model of tumor vascular disruption. The
increase in permeability induced by the tested compounds,
was evaluated in 24-well cell culture, where a confluent
HUVEC monolayer was formed and monitoring the fluo-
rescent signal of FITC-dextran in the lower chamber as a
function of time. As shown in Fig. 4, a significant increase
in endothelial cell permeability was observed when the
confluent monolayers were treated with 10 and 100 nM
TR-644 (panel A) whereas CA-4 (panel B) displayed a
similar profile.
TR-644 is not cytotoxic at the concentrations
that induce vascular effects
To evaluate if the inhibition of cell migration and tube
formation are due to a cytotoxic action of the drug we
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Fig. 2 TR-644 inhibits HUVEC migration. a Confluent HUVEC
monolayer were scratch wounded and the cells were treated with
different concentration of TR-644 or CA-4 and at different times cells
were photographed, 940 magnification; Bar = 10 lm. The dotted
lines define the areas lacking cells. Graphs show the quantitative
effect of TR-644 (b) and CA-4 (c) chosen as reference compound.
Migration was quantified by measuring the gap closure at the
indicated times as showed in a. Data were represented as mean ± -
SEM of three independent experiments. * P \ 0.01 versus control
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analyzed cell proliferation at different times of incubation
by trypan blue count.
As shown in Fig. 5 (panel A), with TR-644 we observed
a modest reduction of the number of cells occurring only at
longer times of incubation (48–72 h). At lower concen-
tration (10 nM), after 24 h of incubation, no reduction of
the viability was found while at 48 and 72 h of incubation
the viability decreased to 38 and 43 % respectively. For
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Fig. 3 Inhibition of endothelial cell capillary-like tubules formation
by TR-644. Tubules formation on Matrigel was carried out as
described in ‘‘Materials and methods’’. a Representative pictures
(910 magnification; Bar = 10 lm) of preformed capillary-like
tubules treated with increasing concentration of TR-644 for 3 h.
b quantitative analysis of the effects of TR-644 and CA4 on the
dimensional and topological parameters of the preformed capillary-
like tubules network. Data were represented as mean ± SEM of three
independent experiments. c Representative pictures (910 magnifica-
tion; Bar = 10 lm) of HUVEC in Matrigel treated with increasing
concentration of TR-644 for 3 h. d quantitative analysis of the effects
of TR-644 and CA4 on the dimensional and topological parameters of
the capillary-like tubules network. Data were represented as
mean ± SEM of three independent experiments
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comparison CA-4 was also evaluated (Fig. 5, panel B) and
we observed a marked reduction of cell number also at the
concentration of 10 nM for which we note a reduction of
about 45 % after 24 h incubation relative to untreated cells.
We also carried out a clonogenic assay in which we
observed that TR-644 had no effect at concentration lower
than 10 nM in comparison to CA4 which was more toxic
than TR-644 of an order of magnitude (Fig. 5, panel C).
To further confirm that TR-644 is not cytotoxic for
endothelial cells we performed flow cytometric Annexin-
V/PI assay of HUVEC cells. As showed in Fig. 5 (panel
D), we observed only a slight reduction of the cell viability
at time points in which, as described above, we observed
antivascular effects of the drug. Even at longer times of
incubation (24 h) and highest concentration (100 nM) no
signes of apoptosis were detected.
TR-644 induces G2/M arrest of the cell cycle
in HUVEC cells
The effect of TR-644 on cell cycle progression was
examined by flow cytometry. TR-644 treatment resulted in
the accumulation of cells in the G2/M phase, with a con-
comitant reduction in the proportion of cells in the G1
phase after 24 h of treatment. These changes started to
occur at the concentration of 10 nM (Fig. 6, panel A). A
small decrease, although not significant, of cells in the S
phase was also observed.
Next, we investigated the association between TR644-
induced G2/M arrest and alterations in G2/M regulatory pro-
tein expression. Cell arrest at the prometaphase/metaphase to
anaphase transition is normally regulated by the mitotic
checkpoint. In eukaryotic cells the activation of Cdc2 kinase is
necessary for occurrence of the G2/M transition of the cell
cycle. Activation of the kinase requires its dephosphorylation
at Tyr15 and Thr14 by the phosphatase Cdc25 and accumu-
lation of the cyclin B protein. As shown in Fig. 6 (panel B),
TR-644 caused a decrease in cyclin B1 expression at 10 nM
while at 100 nM we observed a significant increase. Cdc2Tyr15
and Cdc25 levels decreased both at 10 and 100 nM. Altogether
these results indicate that arrest at G2/M induced by TR-644 is
accompanied by a decreased expression of cyclin B1 at lower
concentration whereas at higher concentration by an increase
and by a remarkable decrease of Cdc25c and p-Cdc2Tyr15.
Effects of TR-644 on microtubules and actin
microfilament in HUVEC cells
We investigated the effects of TR-644 on the cytoskeleton
proteins microtubules and actin micrfilaments. As shown in
Fig. 7, the microtubule network exhibited normal
arrangement and organization in HUVEC cells in the
absence of drug treatment as well as when the cells were
incubated with the lower concentration of drug (1 nM). In
contrast, 24 h of exposure to 10 nM TR-644 caused
microtubule disassembly, with induction, in about 20 % of
the cells, of spherical morphology. Exposure to the com-
pound at 100 nM resulted in an almost complete loss of
microtubules. Similar results were obtained for CA-4
although the observed changes were more marked.
In agreement to the changes in cellular microtubules,
cells treated with TR-644 showed minimal effects in the
arrangement and amount of F-actin (Fig. 8), at low con-
centration (1 nM) respect to the untreated cells. On the
contrary the actin cytoskeleton started to disorganize both
with TR-644 and CA4 (10 nM), resulting in the disap-
pearance of actin fibers and in their relocalization and
reorganization in intracellular focal adhesion regions,
whereas the cytoskeleton was completely altered at higher
concentration of both TR-644 and CA-4.
TR-644 reduces VE-cadherin phosphorylation
VE-cadherin is a member of cadherin superfamily, expressed
by vascular endothelial cells [25]. In these cells, it is the major
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Fig. 4 TR-644 increased the permeability of an endothelial cell layer.
HUVEC cells were seeded onto 0.1 % collagen-coated 24-well insert
wells in complete medium until a confluent monolayer was formed. They
were then treated with the indicated concentrations of TR-644 (a) or CA4
(b). Simultaneously FITC-dextran was also added and its passage into the
lower chamber was monitored at the indicated times. Data were
represented as mean ± SEM of three independent experiments
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adherence junction protein, which, by modulating cell–cell
adhesion, regulates angiogenesis, and vascular permeability.
It is also required for differentiation into vasculature-like
structures by endothelial cells in vitro [26, 27]. Since VE-
cadherin is crucial for controlling the state of adherence
junctions, which in turn regulate endothelial cell–cell adhe-
sion, cell motility, morphogenesis and intracellular signaling
pathways, this molecule has many clinical implications. As
showed above, TR-644 increased HUVEC permeability and
VE-cadherin was mainly non-phosphorylated in quiescent
vessels, thus we evaluated if this compound was able to reduce
VE-cadherin phosphorylation following VEGF stimuli.
VEGF rapidly induced the phosphorylation of VE-cadherin,
triggering modifications of the adherence junction that is
thought to allow for the loosening of cell–cell contacts that
would be required for the sprouting of a new vessel [28]. As
shown in Fig. 9 (panel A), TR-644 remarkably reduced the
VEGF-induced VE-cadherin phosphorylation at Tyr658, both
at 10 and 100 nM. In comparison also CA4 reduced the
phosphorylation as previously demonstrated [29].
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Fig. 5 Effects of TR-644 on
HUVEC cells viability. HUVEC
were plated on onto 0.1 %
collagen-coated 24-wells and
then treated with the indicated
concentrations of TR-644 (a) or
CA4 (b). At different times
(0, 24, 48 and 72 h) cells were
trypsinized and viability was
determined by trypan blue
exclusion assay. Data were
represented as mean ± SEM of
three independent experiments.
c. Representative dishes and
quantitative data on the
inhibitory effects of TR-644 and
CA4 on HUVEC proliferation
evaluated by clonogenic assay.
Data were represented as
mean ± SEM of three
independent experiments.
d. HUVEC plated as described
above were assayed for
apoptosis by flow cytometry
using an Annexin-V/PI assay kit
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VE-cadherin is linked to the actin–myosin cytoskeleton
via b-catenin. The cytoskeleton plays a central role in the
regulation of endothelial permeability and cell migration
by controlling cell shape [4, 30]. Activation of the endo-
thelial contractile machinery and generation of contractile
forces by endothelial cells can cause adjacent cells to
retract from each other.
The linkage of the cytoplasmic region of VE-cadherin
with the actin cytoskeleton is mediated by a number of
proteins, including a- and b-catenin, p120, and plakoglo-
bin, and their interactions with VE-cadherin tend to
strengthen adherens junctions [28]. Immunofluorescent
analysis revealed a partial co-localization of VE-cadherin
and b-catenin in untreated cells at the junctions between
cells (Fig. 9, panel B).
On the other hand, the expression of VE-cadherin was
strongly reduced in the presence of TR-644 both at 10 and
100 nM. More importantly, the cell–cell contacts appeared
destroyed by the treatment and in control cells, VE-cad-
herin staining occurs on the surface suggesting that TR-644
is able to disrupt the cadherin/catenin complex and that the
disruption of this complex may be responsible for the
disruption in cell–cell adhesion.
TR-644 induces increase of cell adhesion
without interfering with focal adhesion kinase (FAK)
Focal adhesion kinase (FAK) is a 125-kDa non-receptor
tyrosine kinase, which acts as a scaffold at sites of cell
attachment to the extracellular matrix (ECM) and is acti-
vated following binding of integrins to ECM or upon
growth factor stimulation including VEGF [31–33]. As a
result, it regulates cell shape, cell adhesion and cell
motility [33]. Since TR-644 inhibits cell migration, we
examined if it is able to inhibit the formation of focal
adhesions and the VEGF-induced phosphorylation of FAK.
As shown in Fig. 9 (panel A), VEGF induced an increase
of FAK phosphorylation at Tyr397 while the treatment
with TR-644 slight increased its phosphorylation, both at
10 and 100 nM. CA4 also increased the expression of
FAKTyr397. To further investigate the effect of TR-644 on
FAK we analyzed HUVEC cells by immunofluorescence.
As showed in Fig. 9 (panel C), we observed that focal
adhesions were distributed in a punctiform pattern along
the cell periphery and TR-644 did not change the expres-
sion of focal adhesion both in the absence and in presence
of VEGF. These results could appear in contrast with the
inhibition of cell migration induced by the compound,
indeed they are consistent with the increase in HUVEC
cells adhesion induced by TR-644 (Fig. 9, panel D).
TR-644 treatment inhibits in vivo angiogenesis in CAM
assay
TR-644 was assessed for its anti-angiogenic activity in vivo
on the chick embryo chorioallantoic membrane (CAM). To
this purpose, alginate beads containing FGF were applied
topically on the CAM at day 11 of development in the
absence or in the presence of TR-644 or CA4. As showed in
Fig. 10 (panels A and B), FGF alone, triggered a potent
angiogenic response that was significantly inhibited by TR-
644 (panel A), also at the lowest concentration used
(0.01 nmol/egg). Interestingly, TR-644 did not induce any
effect on the basal vascularization of the CAM and did not
affect the development and survival of the chick embryos
(data not shown). In contrast, CA4 (panel B) in the absence
of FGF, induced a significant increase of the basal vascu-
lature at all the concentration used. It has recently been
shown, that the formation of new vessels in CAM could be
driven by a pro-inflammatory signature, characterized by
the upregulation of proinflammatory cytokine/chemokines
and their receptors, endothelial cells adhesion molecules,
and members of the eicosanoid pathway [34]. Thus, this
effect could be due to an inflammatory response triggered
by cellular damage induced by CA-4. Indeed hematoxylin-
heosin staining of the CAM showed a remarkable appear-
ance of multiple site of inflammation along with the
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Fig. 6 a Effect of compound TR-644 on cell cycle distribution of
HUVEC cells. Cells were treated with different concentrations,
ranging from 1 to 100 nM for 24 h. Then the cells were fixed and
stained with PI to analyze DNA content by flow cytometry. Data are
presented as mean ± SEM of three independent experiments.
b Effect of TR-644 on G2/M regulatory proteins. HUVEC cells were
treated for 24 h with the indicated concentrations. The cells were
harvested and lysed for the detection of cyclin B, p-cdc2Tyr15 and
cdc25c expression by western blot analysis. To confirm equal protein
loading, each membrane was stripped and reprobed with anti-b-actin
antibody
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recruitment of lymphocytes and macrophages in CA4-
treated samples (Fig. 10, panel C).
TR-644 disrupts tumor vasculature in vivo tumor model
BL6-B16 mouse melanoma cell line were injected s.c. in
syngeneic C57BL/6 mice. CD31 is expressed on vessels
and is the most specific and sensitive endothelial marker
currently available. A single i.p. administration of TR-644
(30 mg/Kg) significantly reduced tumor blood vasculature
as determined by immunohistochemical staining with the
antibody reactive to CD31 in brown color (Fig. 11, panel
B). Also CA4-P significantly reduced the number of CD31
positive cells per field in well agreement with previous
reports [29].
Moreover, we also tested whether TR-644 causes his-
tological changes in tumor tissue by staining with hema-
toxilin and eosin (HE) and measuring proliferation using
PCNA staining. The HE staining suggested that 24 h after a
Fig. 7 Effect of TR-644 on
microtubules in HUVEC. Cells
were incubated for 24 h with the
indicated concentration of TR-
644 or CA-4 as comparison and
stained with anti-b-tubulin
primary antibody and secondary
Alexa-conjugated antibody and
then observed by confocal
microscopy (magnification 920
Bar = 10 lm). Cells were also
counterstained with DAPI to
visualize the nuclei. Insets
represent magnification at 960,
of a portion of the field
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single i.p. injection of TR-644, there was a massive area of
necrosis within tumor for both compounds. The number of
PCNA positive cells, can be used as an index of cell pro-
liferation. As showed in Fig. 11 (panel C), cell prolifera-
tion in the whole tumor significantly decreased after TR-
644, while CA4-P did not. These results are in well
agreement with the higher antiproliferative activity of TR-
644 in many tumor cell lines relative to the lead compound
CA-4 [15].
Discussion
We previously demonstrated that TR-644 displayed effec-
tive antiproliferative activity in numerous cell lines derived
from human solid tumors and leukemias, including multi-
drug resistant cell lines [15]. We also showed that TR-644
induced depolymerization of tubulin and inhibited normal
spindle formation in HeLa cells, resulting in mitotic arrest
and cell death. The inhibition of tubulin polymerization
Fig. 8 Effect of TR-644 on
actin microfilaments in
HUVEC. Cells were incubated
for 24 h with the indicated
concentration of TR-644 or CA-
4 as comparison and stained
with phalloidin-
tetramethylrhodamine B
isothiocyanate conjugate. Cells
were also counterstained with
DAPI to visualize the nuclei
(magnification 960)
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was similar to that observed with the reference compound
CA4. Examination of the effects of TR-644 on [3H]col-
chicine binding to tubulin revealed that colchicine binding
was efficiently inhibited, indicating that TR644 binds
tubulin in the colchicine site.
In this study, we demonstrated that TR-644 is a potent
vascular disrupting agent that exhibit antivascular activity
both in vitro and in vivo experiments. Motility and
migration of vascular endothelial cells are important in the
angiogenic process. We found that TR-644, at namolar
concentration range, induces a significant inhibitory effect
on endothelial cell migration. In addition, TR-644 inhibits
both the organization of HUVEC into vessel-like tubes and
disrupts established endothelial cell tubes in a concentra-
tion dependent manner. These effects are similar to that of
the lead compound CA4.
Given the correlation between G2/M phase arrest and
cytoskeletal dynamics, we investigated the effect of TR-
644 on the cell cycle. As other microtubule-binding agents
TR-644 induces a G2/M phase arrest along with a
remarkable reduction of the G1 phase while the S phase
is only slight affected. During a normal cell cycle, the
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Fig. 10 In vivo effects of TR-644 (a) and CA4 (b) on chorioallantoic
membrane (CAM) assay. Alginate sponges embedded with FGF
(150 ng), a stimulator of blood vessel formation, in the presence of
the indicated doses of compounds were implanted on the top of the
growing CAM on day 11 of development. On day 14, newly formed
blood vessels converging toward the implants are counted at
microscopic levels. Data represent mean ± SEM of at least 10 eggs
for groups. * P \ 005; ** P \ 0.01 versus control. c Histological
pictures obtained from the CAM assay in the absence of FGF
(hematoxylin–eosin staining 960 magnification)
Fig. 9 Effect of TR-644 on VE-cadherin and FAK. a Western blot
analysis of VE-CadherinY658 and FAKY397 after 6 h of treatment with
TR-644 and CA-4 at the indicated concentration in the presence of
VEGF. b Immunofluorescence analysis of HUVEC cells treated with
the indicated concentration of TR644 for 6 h and then stained with
anti b-catenin antibody and anti VE-cadherinY658 antibody. Cells
were also counterstained with DAPI to visualize the nuclei (magni-
fication 940). c Immunofluorescence analysis of HUVEC cells
treated with the indicated concentration of TR-644 for 6 h and then
stained with anti b-tubulin antibody and anti FAKY397 antibody. Cells
were also counterstained with DAPI to visualize the nuclei (magni-
fication 940). Arrows indicate focal adhesions. d TR-644 enhances
HUVEC cell adhesion. Data represent mean ± SEM of three
independent experiments performed in triplicate
b
Angiogenesis (2013) 16:647–662 659
123
progression of cells in the G2 phase to M phase is triggered
by the activation of the cyclin B1-dependent Cdc2 kinase
[35, 36], which is regulated by a series of phosphorylation-
dephosphorylation events and protein–protein interactions
[37]. At the G2/M phase transition, Cdc2 is dephospho-
rylated on Tyr15 and Thr14 and this event lead to activation
of the Cdc2 kinase and entry of cells into mitosis. Treat-
ment with TR-644 decreases the phosphorylation of at
Cdc2 at Tyr15 and the expression of the phosphatase Cd25c
both at 10 and 100 nM. Curiously enough we observed a
dual effect of TR-644 on cyclin B1 expression: while at
10 nM we observed a down regulation of cyclin B1
expression at higher concentration we found the opposite.
This could be due to the fact that at low concentration a
part of the cells are still able to exit from mitosis, while at
higher concentration the cell arrest becomes irreversible
and consequently the cyclin B1 expression increased.
TR-644 increases vascular permeability probably by
disrupting endothelial cell–cell contact, and preventing
organization of cellular connections that are critical for
their survival and maintenance. These effects could be
attributed to the inhibition of VE-cadherin phosphoryla-
tion. Indeed TR-644 strongly inhibits the phosphorylation
of VE-cadherin induced by VEGF and reduces cell–cell
contacts. Interestingly such analysis also clearly show a
dissociation of the VE-cadherin/b-catenin complex. Since
VE-cadherin is linked and interacts with actin fibers via b-
catenin, it is reasonable that the effect of TR-644 on
cytoskeleton may contribute to the disconnection of hom-
ophilic VE-cadherin/b-catenin–mediated cell–cell interac-
tions. In this context it is worthwhile to note that also CA4
was demonstrated to increase endothelial cell permeability
through disruption of the VE-cadherin/b-catenin signaling
[29].
It is interesting to note that all these effects occur at
concentration that per se did not induce significant effects
on endothelial cell proliferation while it appears that in
HUVEC TR-644 is endowed with a lower cytotoxicity in
comparison to the lead compound CA4.
FAK plays a central role during focal adhesion complex
assembly and disassembly, that are critical for cell adhe-
sion and migration. When FAK is activated, it is auto-
phosphorylated at its autophosphorylation site Tyr397,
binds to Src, which in turn phosphorylates other sites on
FAK and the FAK-binding proteins, such as Cas and
paxillin, which modulates cytoskeleton re-arrangement
[31]. Moreover, inhibition of FAK phosphorylation greatly
impairs cell spreading and adhesion [31]. Some anti mitotic
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Fig. 11 Efficacy in vivo of TR-644 in a syngeneic mouse model.
BL6-B16 murine melanoma cells were injected in the right flank of
C57BL/6 mice as described in ‘‘Materials and methods’’. Tumor
tissues were embedded in OCT-compound and frozen for immuno-
histochemistry. a CD31 immunohistochemistry and hematoxylin–
eosin (HE) staining of tumor after i.p. treatment with 30 mg/kg of
both TR-644 or CA4-P (9100 magnification). b Quantitative analysis
of tumor section stained with CD31. Data are represented as
mean ± SEM of five mouse per group * P \ 0.05 versus control.
c Quantitative analysis of tumor section stained with PCNA. Data are
represented as mean ± SEM of five mouse per group * P \ 0.05
versus control
b
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drugs such as laulilamide [38] and taxotere [39] have been
previously found to block the formation of focal adhesion
and the autophosphorylation of FAK.
However, in TR-644-treated HUVEC, we found that
FAK phosphorylation at Tyr397 is slight increased com-
pared with the VEGF-treated cells. These high levels of
FAKTyr397 could prevent focal adhesion disassembly,
leading to impaired cell migration. Recent evidences sug-
gest that the level of phosphorylated FAK increases during
focal adhesion formation [40]. The behavior of TR-644 is
similar to JG-03-14, a new substituted pyrrole derivative
which has been showed to affect endothelial cells function
through inhibition of VE-cadherin but without interfering
with FAK phosphorylation or focal adhesion formation
[41]. It is worth noting that TR-644 increases actin stress
fiber formation and in a recent study [42], the increased
formation of intracellular stress fibers were correlated with
enhanced cell adhesion in mammary cells, whereas
migrating cells had fewer stress fibers. Indeed we also
found that TR-644 significantly increases HUVEC adhe-
sion suggesting that inhibition of cell migration may be
linked to an activation of FAK signaling. To evaluate the
ability of the TR-644 to interfere with the angiogenic
process in vivo, we used the CAM assay as a model of
neovessel formation, and observed that TR-644 signifi-
cantly reduces the number of newly formed vessels in the
CAM even at very low doses (0.01 nmol/egg). The effect
was observed in the absence of any effect on embryonic
development and survival and TR-644 had no toxic effects
on preexisting vessels (data not shown). This is in accor-
dance with our in vitro findings that showed a lower
cytotoxicity of TR-644 respect to CA4. Surprisingly CA4
at all concentration tested induces per se a significant
increase of the vasculature mimicking the effects of FGF.
Recent papers [34, 43], indicate that inflammatory cyto-
kines, as early mediators of inflammation, are a potent
angiogenic factors, suggesting that angiogenesis and
inflammation are closely integrated processes. In this
context the pro-angiogenic effect of CA4 in the absence of
FGF could be due to a cell damage effect of CA4 that in
some way produces the recruitment of inflammatory cells
that consequently induces neovascularization. Accordingly,
histological examination of CAM showed a remarkable
monocyte/macrophage infiltrate in the area in which the
alginate pellet containing CA4 was located. It is worth-
while to note that anti-inflammatory agents exert antian-
giogenic effects. Further in vivo experiments carried out
with mouse melanoma tumor model demonstrated that a
single injection of TR-644 efficiently and selectively
destroy vasculature of tumor tissue and induce a significant
reduction of tumor cell proliferation as demonstrated by
reduction in PCNA positive cells. In summary our study
provides for the first time evidence that administration of
TR-644 causes inhibition of angiogenesis both in vitro and
in vivo at a concentration that is not cytotoxic for endo-
thelial cells indicating that TR-644 may be a promising
candidate as inhibitor of angiogenesis.
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